During the past few decades, the incidence of thyroid cancer has increased substantially in
many countries, including the USA. The rise in incidence seems to be attributable both to the …

Thyroid cancer is a common endocrine malignancy. There has been exciting progress in
understanding its molecular pathogenesis in recent years, as best exemplified by the …

We use deep transfer learning to quantify histopathological patterns across 17,355
hematoxylin and eosin-stained histopathology slide images from 28 cancer types and …

Thyroid cancer is a common type of endocrine malignancy, and its incidence has been
steadily increasing in many regions of the world. Initiation and progression of thyroid cancer …

Substantial developments have occurred in the past 5–10 years in clinical translational
research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and …

Purpose: To determine whether the selective BRAF inhibitor, dabrafenib, can stimulate
radioiodine uptake in BRAF V600E-mutated unresectable or metastatic iodine-refractory …

Thyroid cancer comprises a broad spectrum of diseases with variable prognoses. Although
most patients with this disease have excellent overall survival, there are some who do not …

In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged
progression-free survival (PFS) in patients with metastatic pancreatic/intestinal …

BACKGROUND: The effects of the BRAFV600E mutation on prognostic factors and poor
clinical outcomes in papillary thyroid cancer (PTC) have not been fully quantified. The …

In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …